SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 39.02 USD 7.49% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
SpringWorks Therapeutics Inc?
Write Note

Intrinsic Value

SWTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SWTX stock under the Base Case scenario is 42.61 USD. Compared to the current market price of 39.02 USD, SpringWorks Therapeutics Inc is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SWTX Intrinsic Value
42.61 USD
Undervaluation 8%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
SpringWorks Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SWTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SWTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about SpringWorks Therapeutics Inc

Provide an overview of the primary business activities
of SpringWorks Therapeutics Inc.

What unique competitive advantages
does SpringWorks Therapeutics Inc hold over its rivals?

What risks and challenges
does SpringWorks Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in SpringWorks Therapeutics Inc recently?

Summarize the latest earnings call
of SpringWorks Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for SpringWorks Therapeutics Inc.

Provide P/S
for SpringWorks Therapeutics Inc.

Provide P/E
for SpringWorks Therapeutics Inc.

Provide P/OCF
for SpringWorks Therapeutics Inc.

Provide P/FCFE
for SpringWorks Therapeutics Inc.

Provide P/B
for SpringWorks Therapeutics Inc.

Provide EV/S
for SpringWorks Therapeutics Inc.

Provide EV/GP
for SpringWorks Therapeutics Inc.

Provide EV/EBITDA
for SpringWorks Therapeutics Inc.

Provide EV/EBIT
for SpringWorks Therapeutics Inc.

Provide EV/OCF
for SpringWorks Therapeutics Inc.

Provide EV/FCFF
for SpringWorks Therapeutics Inc.

Provide EV/IC
for SpringWorks Therapeutics Inc.

Show me price targets
for SpringWorks Therapeutics Inc made by professional analysts.

What are the Revenue projections
for SpringWorks Therapeutics Inc?

How accurate were the past Revenue estimates
for SpringWorks Therapeutics Inc?

What are the Net Income projections
for SpringWorks Therapeutics Inc?

How accurate were the past Net Income estimates
for SpringWorks Therapeutics Inc?

What are the EPS projections
for SpringWorks Therapeutics Inc?

How accurate were the past EPS estimates
for SpringWorks Therapeutics Inc?

What are the EBIT projections
for SpringWorks Therapeutics Inc?

How accurate were the past EBIT estimates
for SpringWorks Therapeutics Inc?

Compare the revenue forecasts
for SpringWorks Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of SpringWorks Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of SpringWorks Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of SpringWorks Therapeutics Inc compared to its peers.

Compare the P/E ratios
of SpringWorks Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing SpringWorks Therapeutics Inc with its peers.

Analyze the financial leverage
of SpringWorks Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for SpringWorks Therapeutics Inc.

Provide ROE
for SpringWorks Therapeutics Inc.

Provide ROA
for SpringWorks Therapeutics Inc.

Provide ROIC
for SpringWorks Therapeutics Inc.

Provide ROCE
for SpringWorks Therapeutics Inc.

Provide Gross Margin
for SpringWorks Therapeutics Inc.

Provide Operating Margin
for SpringWorks Therapeutics Inc.

Provide Net Margin
for SpringWorks Therapeutics Inc.

Provide FCF Margin
for SpringWorks Therapeutics Inc.

Show all solvency ratios
for SpringWorks Therapeutics Inc.

Provide D/E Ratio
for SpringWorks Therapeutics Inc.

Provide D/A Ratio
for SpringWorks Therapeutics Inc.

Provide Interest Coverage Ratio
for SpringWorks Therapeutics Inc.

Provide Altman Z-Score Ratio
for SpringWorks Therapeutics Inc.

Provide Quick Ratio
for SpringWorks Therapeutics Inc.

Provide Current Ratio
for SpringWorks Therapeutics Inc.

Provide Cash Ratio
for SpringWorks Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for SpringWorks Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for SpringWorks Therapeutics Inc?

What is the current Free Cash Flow
of SpringWorks Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for SpringWorks Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
SpringWorks Therapeutics Inc

Current Assets 435.1m
Cash & Short-Term Investments 376.6m
Receivables 33m
Other Current Assets 25.5m
Non-Current Assets 173.8m
Long-Term Investments 127.1m
PP&E 25.4m
Other Non-Current Assets 21.3m
Current Liabilities 70.6m
Accounts Payable 9.7m
Accrued Liabilities 61m
Non-Current Liabilities 5.7m
Other Non-Current Liabilities 5.7m
Efficiency

Earnings Waterfall
SpringWorks Therapeutics Inc

Revenue
135.5m USD
Cost of Revenue
-7.4m USD
Gross Profit
128.1m USD
Operating Expenses
-423.3m USD
Operating Income
-295.3m USD
Other Expenses
20.1m USD
Net Income
-275.2m USD

Free Cash Flow Analysis
SpringWorks Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In its third quarter, SpringWorks Therapeutics celebrated a 23% quarter-over-quarter increase in OGSIVEO revenue, totaling $49.3 million, contributing to year-to-date earnings of $110.5 million. The firm remains confident in achieving profitability by mid-2026 and is expanding its market presence for OGSIVEO and mirdametinib. With an anticipated marketing approval for mirdametinib in February 2025, aimed at addressing a significant unmet need in NF1-PN patients, and ongoing positive patient outcomes with OGSIVEO, SpringWorks is poised for continued growth, driven by a robust clinical and commercial strategy.

What is Earnings Call?
Fundamental Scores

SWTX Profitability Score
Profitability Due Diligence

SpringWorks Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive Gross Profit
30/100
Profitability
Score

SpringWorks Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

SWTX Solvency Score
Solvency Due Diligence

SpringWorks Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

SpringWorks Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SWTX Price Targets Summary
SpringWorks Therapeutics Inc

Wall Street analysts forecast SWTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SWTX is 69.05 USD with a low forecast of 58.58 USD and a high forecast of 84 USD.

Lowest
Price Target
58.58 USD
50% Upside
Average
Price Target
69.05 USD
77% Upside
Highest
Price Target
84 USD
115% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SWTX?

Click here to dive deeper.

Dividends

SpringWorks Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SWTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SWTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.9B USD

Dividend Yield

0%

Description

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 176 full-time employees. The company went IPO on 2019-09-13. The firm is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.

Contact

CONNECTICUT
Stamford
100 Washington Blvd
+12038839490.0
www.springworkstx.com

IPO

2019-09-13

Employees

176

Officers

CEO & Director
Mr. Saqib Islam J.D.
Chief Financial Officer
Mr. Francis I. Perier Jr., M.B.A.
Chief Operating Officer
Dr. Badreddin Edris Ph.D.
Chief Medical Officer
Dr. James Cassidy M.D., Ph.D.
Chief Accounting Officer
Mr. Michael P. Nofi
Chief Scientific Officer
Mr. Tai-An Lin Ph.D.
Show More
Vice President of Communications & Investor Relations
Ms. Kim Diamond
General Counsel & Secretary
Mr. Herschel S. Weinstein J.D.
Chief People Officer
Mr. Daniel J. Pichl
Chief Commercial Officer
Mr. Bhavesh Ashar M.B.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one SWTX stock?

The intrinsic value of one SWTX stock under the Base Case scenario is 42.61 USD.

Is SWTX stock undervalued or overvalued?

Compared to the current market price of 39.02 USD, SpringWorks Therapeutics Inc is Undervalued by 8%.

Back to Top